4 January 2024 Kyverna’s KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial read more
3 January 2024 Alterome Named BioSpace’s NextGen Class of 2024: Top Life Sciences Startups to Watch This Year read more
3 January 2024 Aktis Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference read more